United Services Automobile Association Makes New Investment in Medpace Holdings, Inc. $MEDP

Key Points

• United Services Automobile Association has acquired a new position in Medpace Holdings, Inc., purchasing 1,601 shares valued at approximately $500,000.
• Medpace reported earnings of $3.10 per share for the latest quarter, exceeding analysts' expectations, with revenues up 14.2% year-over-year.
• Several analysts have revised their price targets for Medpace, with Deutsche Bank raising its target from $270 to $430 and Cowen downgrading from a "buy" to a "sell" rating.

United Services Automobile Association acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 1,601 shares of the company's stock, valued at approximately $500,000.

Several other large investors also recently added to or reduced their stakes in the stock. Whittier Trust Co. increased its stake in Medpace by 47.3% during the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after acquiring an additional 35 shares during the last quarter. Benjamin Edwards Inc. increased its stake in Medpace by 3.1% during the first quarter. Benjamin Edwards Inc. now owns 1,201 shares of the company's stock worth $366,000 after acquiring an additional 36 shares during the last quarter. Assetmark Inc. increased its stake in Medpace by 24.9% during the first quarter. Assetmark Inc. now owns 216 shares of the company's stock worth $66,000 after acquiring an additional 43 shares during the last quarter. Proficio Capital Partners LLC increased its stake in Medpace by 6.4% during the first quarter. Proficio Capital Partners LLC now owns 777 shares of the company's stock worth $237,000 after acquiring an additional 47 shares during the last quarter. Finally, Park Avenue Securities LLC increased its stake in Medpace by 1.8% during the first quarter. Park Avenue Securities LLC now owns 2,749 shares of the company's stock worth $838,000 after acquiring an additional 48 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $476.69 on Thursday. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $501.30. The business has a 50 day simple moving average of $422.55 and a two-hundred day simple moving average of $347.11. The firm has a market capitalization of $13.39 billion, a PE ratio of 35.44, a price-to-earnings-growth ratio of 3.06 and a beta of 1.44.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. The firm had revenue of $603.31 million during the quarter, compared to analyst estimates of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.Medpace's quarterly revenue was up 14.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Equities research analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Deutsche Bank Aktiengesellschaft boosted their price objective on Medpace from $270.00 to $430.00 and gave the stock a "hold" rating in a research note on Wednesday, July 23rd. Cowen lowered Medpace from a "buy" rating to a "sell" rating in a research report on Wednesday, July 23rd. Truist Financial boosted their target price on Medpace from $298.00 to $436.00 and gave the company a "hold" rating in a research report on Wednesday, July 23rd. Jefferies Financial Group boosted their target price on Medpace from $400.00 to $450.00 and gave the company a "hold" rating in a research report on Tuesday. Finally, Robert W. Baird boosted their target price on Medpace from $313.00 to $490.00 and gave the company a "neutral" rating in a research report on Wednesday, July 23rd. Two analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Medpace currently has a consensus rating of "Reduce" and an average target price of $422.27.

Insider Transactions at Medpace

In related news, General Counsel Stephen P. Ewald sold 3,000 shares of the business's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $450.00, for a total value of $1,350,000.00. Following the completion of the sale, the general counsel owned 10,343 shares in the company, valued at approximately $4,654,350. The trade was a 22.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO August J. Troendle sold 36,196 shares of the business's stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $475.90, for a total value of $17,225,676.40. Following the completion of the sale, the chief executive officer owned 925,799 shares of the company's stock, valued at $440,587,744.10. The trade was a 3.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 161,266 shares of company stock valued at $74,111,427 in the last ninety days. Corporate insiders own 20.30% of the company's stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.